Canopy Growth Corp 10-Q

Item 1. Financial Statements. CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (in thousands of Canadian dollars, except number of shares and per share data, unaudited) December 31, 2021 March 31, 2021 ASSETS Current assets: Cash and cash equivalents $ 615,146 $ 1,154,653 Short-term investments 807,884 1,144,563 Restricted short-term investments 12,208 11,332 Amounts receivable, net 100,901 92,435 Inventory 365,750 367,979 Prepaid expenses and other assets 86,267 67,232 Total current assets 1,988,156 2,838,194 Other financial assets 898,497 708,167 Property, plant and equipment 1,080,179 1,074,537 Intangible assets 338,753 308,167 Goodwill 1,988,250 1,889,354 Other assets 15,195 5,061 Total assets $ 6,309,030 $ 6,823,480 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 67,837 $ 67,262 Other accrued expenses and liabilities 76,007 100,813 Current portion of long-term debt 15,702 9,827 Other liabilities 79,700 106,428 Total current liabilities 239,246 284,330 Long-term debt 1,494,665 1,573,136 Deferred income tax liabilities 27,366 21,379 Liability arising from Acreage Arrangement 103,000 600,000 Warrant derivative liability 37,491 615,575 Other liabilities 195,618 107,240 Total liabilities 2,097,386 3,201,660 Commitments and contingencies Redeemable noncontrolling interest 68,700 135,300 Canopy Growth Corporation shareholders' equity: Common shares - $nil par value; Authorized - unlimited number of shares; Issued - 394,157,998 shares and 382,875,179 shares, respectively 7,478,834 7,168,557 Additional paid-in capital 2,482,372 2,415,650 Accumulated other comprehensive loss ( 26,727 ) ( 34,240 ) Deficit ( 5,795,721 ) ( 6,068,156 ) Total Canopy Growth Corporation shareholders' equity 4,138,758 3,481,811 Noncontrolling interests 4,186 4,709 Total shareholders' equity 4,142,944 3,486,520 Total liabilities and shareholders' equity $ 6,309,030 $ 6,823,480 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 1 CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (in thousands of Canadian dollars, except number of shares and per share data, unaudited) Three months ended December 31, Nine months ended December 31, 2021 2020 2021 2020 Revenue $ 155,024 $ 169,907 $ 456,095 $ 439,823 Excise taxes 14,052 17,379 47,540 41,613 Net revenue 140,972 152,528 408,555 398,210 Cost of goods sold 130,882 127,943 442,367 341,050 Gross margin 10,090 24,585 ( 33,812 ) 57,160 Operating expenses Selling, general and administrative expenses 116,835 144,078 355,165 426,723 Share-based compensation 6,777 19,963 35,856 72,632 Expected credit losses on financial assets and related charges - 13,735 - 108,480 Asset impairment and restructuring costs 36,439 400,422 128,198 459,579 Total operating expenses 160,051 578,198 519,219 1,067,414 Operating loss ( 149,961 ) ( 553,613 ) ( 553,031 ) ( 1,010,254 ) Loss from equity method investments - ( 671 ) ( 100 ) ( 40,851 ) Other income (expense), net 34,282 ( 290,567 ) 810,769 ( 21,106 ) (Loss) income before income taxes ( 115,679 ) ( 844,851 ) 257,638 ( 1,072,211 ) Income tax recovery 183 15,600 490 18,086 Net (loss) income ( 115,496 ) ( 829,251 ) 258,128 ( 1,054,125 ) Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest ( 6,571 ) 75,129 ( 14,307 ) ( 9,183 ) Net (loss) income attributable to Canopy Growth Corporation $ ( 108,925 ) $ ( 904,380 ) $ 272,435 $ ( 1,044,942 ) Basic (loss) earnings per share $ ( 0.28 ) $ ( 2.43 ) $ 0.70 $ ( 2.83 ) Basic weighted average common shares outstanding 393,818,282 372,908,767 390,423,083 369,418,037 Diluted (loss) earnings per share $ ( 0.28 ) $ ( 2.43 ) $ 0.43 $ ( 2.83 ) Diluted weighted average common shares outstanding 393,818,282 372,908,767 410,986,802 369,418,037 Comprehensive income (loss): Net (loss) income $ ( 115,496 ) $ ( 829,251 ) $ 258,128 $ ( 1,054,125 ) Other comprehensive income (loss), net of income tax effect Fair value changes of own credit risk of financial liabilities 16,200 ( 30,090 ) 26,280 ( 82,560 ) Foreign currency translation ( 15,479 ) ( 45,809 ) ( 18,767 ) ( 110,932 ) Total other comprehensive income (loss), net of income tax effect 721 ( 75,899 ) 7,513 ( 193,492 ) Comprehensive income (loss) ( 114,775 ) ( 905,150 ) 265,641 ( 1,247,617 ) Comprehensive income (loss) attributable to noncontrolling interests and redeemable noncontrolling interest ( 6,571 ) 75,129 ( 14,307 ) ( 9,183 ) Comprehensive income (loss) attributable to Canopy Growth Corporation $ ( 108,204 ) $ ( 980,279 ) $ 279,948 $ ( 1,238,434 ) The accompanying notes are an integral part of these condensed interim consolidated financial statements. 2 CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (in thousands of Canadian dollars, unaudited) Additional paid-in capital Accumulated Common shares Share-based reserve Warrants Ownership changes Redeemable noncontrolling interest other comprehensive income (loss) Deficit Noncontrolling interests Total Balance at March 31, 2021 $ 7,168,557 $ 480,786 $ 2,568,438 $ ( 512,340 ) $ ( 121,234 ) $ ( 34,240 ) $ ( 6,068,156 ) $ 4,709 $ 3,486,520 Other issuances of common shares and warrants 296,574 ( 30,126 ) - - - - - - 266,448 Replacement equity instruments from the acquisition of Supreme Cannabis - 5,566 13,350 - - - - - 18,916 Exercise of Omnibus Plan stock options 8,690 ( 3,235 ) - - - - - - 5,455 Share-based compensation - 35,172 - - - - - - 35,172 Issuance and vesting of restricted share units 5,013 ( 5,013 ) - - - - - - - Changes in redeemable noncontrolling interest - - - - 53,500 - - 13,100 66,600 Ownership changes relating to noncontrolling interests - - - - - - - 684 684 Redemption of redeemable noncontrolling interest - - - 2,617 ( 5,109 ) - - - ( 2,492 ) Comprehensive income (loss) - - - - - 7,513 272,435 ( 14,307 ) 265,641 Balance at December 31, 2021 $ 7,478,834 $ 483,150 $ 2,581,788 $ ( 509,723 ) $ ( 72,843 ) $ ( 26,727 ) $ ( 5,795,721 ) $ 4,186 $ 4,142,944 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 3 CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (in thousands of Canadian dollars, unaudited) Additional paid-in capital Accumulated Common shares Share-based reserve Warrants Ownership changes Redeemable noncontrolling interest other comprehensive income (loss) Deficit Noncontrolling interests Total Balance at March 31, 2020 $ 6,373,544 $ 517,741 $ 2,638,951 $ ( 501,403 ) $ ( 40,134 ) $ 220,899 $ ( 4,323,236 ) $ 221,758 $ 5,108,120 Other issuances of common shares and warrants 35,666 ( 27,721 ) - - - - - - 7,945 Exercise of warrants 315,256 - ( 70,266 ) - - - - - 244,990 Exercise of Omnibus Plan stock options 61,167 ( 23,168 ) - - - - - - 37,999 Share-based compensation - 69,243 - - - - - - 69,243 Issuance and vesting of restricted share units 2,092 ( 2,092 ) - - - - - - - Changes in redeemable noncontrolling interest - - - - ( 51,230 ) - - 9,880 ( 41,350 ) Ownership changes relating to noncontrolling interests - - - ( 243 ) - - - 5,335 5,092 Comprehensive income (loss) - - - - - ( 193,492 ) ( 1,044,942 ) ( 9,183 ) ( 1,247,617 ) Balance at December 31, 2020 $ 6,787,725 $ 534,003 $ 2,568,685 $ ( 501,646 ) $ ( 91,364 ) $ 27,407 $ ( 5,368,178 ) $ 227,790 $ 4,184,422 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 4 CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands of Canadian dollars, unaudited) Nine months ended December 31, 2021 2020 Cash flows from operating activities: Net income (loss) $ 258,128 $ ( 1,054,125 ) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation of property, plant and equipment 56,467 54,625 Amortization of intangible assets 27,462 43,565 Share of loss on equity method investments 100 40,851 Share-based compensation 35,856 72,632 Asset impairment and restructuring costs 113,250 422,610 Expected credit losses on financial assets and related charges - 108,480 Income tax recovery ( 490 ) ( 18,086 ) Non-cash fair value adjustments ( 893,024 ) 26,060 Change in operating assets and liabilities, net of effects from purchases of businesses: Amounts receivable 4,083 ( 12,507 ) Prepaid expenses and other assets 6,702 ( 4,353 ) Inventory 28,818 ( 2,937 ) Accounts payable and accrued liabilities ( 30,764 ) 13,094 Other, including non-cash foreign currency ( 25,713 ) ( 57,808 ) Net cash used in operating activities ( 419,125 ) ( 367,899 ) Cash flows from investing activities: Purchases of and deposits on property, plant and equipment ( 36,620 ) ( 137,977 ) Purchases of intangible assets ( 4,564 ) ( 7,238 ) Proceeds on sale of property, plant and equipment 25,660 30,921 Proceeds on sale of intangible assets - 18,337 (Purchases) redemption of short-term investments 340,218 ( 83,612 ) Net cash proceeds on sale of subsidiaries 10,324 - Sale of equity method investments - 7,000 Investment in other financial assets ( 374,414 ) ( 34,236 ) Investment in Acreage Arrangement - ( 49,849 ) Loan advanced to Acreage Hempco - ( 66,995 ) Net cash outflow on acquisition of subsidiaries ( 14,947 ) - Other investing activities ( 16,759 ) ( 5,269 ) Net cash used in investing activities ( 71,102 ) ( 328,918 ) Cash flows from financing activities: Proceeds from issuance of common shares and warrants 1,460 - Proceeds from exercise of stock options 5,455 37,999 Proceeds from exercise of warrants - 244,990 Repayment of long-term debt ( 50,217 ) ( 13,271 ) Other financing activities ( 3,036 ) ( 578 ) Net cash (used in) provided by financing activities ( 46,338 ) 269,140 Effect of exchange rate changes on cash and cash equivalents ( 2,942 ) ( 50,539 ) Net decrease in cash and cash equivalents ( 539,507 ) ( 478,216 ) Cash and cash equivalents, beginning of period 1,154,653 1,303,176 Cash and cash equivalents, end of period $ 615,146 $ 824,960 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 5 CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands of Canadian dollars, unaudited) Nine months ended December 31, 2021 2020 Supplemental disclosure of cash flow information Cash received during the period: Income taxes $ 993 $ 4,176 Interest $ 10,844 $ 19,078 Cash paid during the period: Income taxes $ 2,641 $ 20,376 Interest $ 83,968 $ 12,886 Noncash investing and financing activities Additions to property, plant and equipment $ ( 5,145 ) $ 16,220 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 6 CANOPY GROWTH CORPORATION NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (in thousands of Canadian dollars, unaudited) 1 . DESCRIPTION OF BUSINESS Canopy Growth Corporation is a publicly traded corporation, incorporated in Canada, with its head office located at 1 Hershey Drive, Smiths Falls, Ontario. References herein to “Canopy Growth” or “the Company” refer to Canopy Growth Corporation and its subsidiaries. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult recreational and medical purposes under a portfolio of distinct brands in Canada pursuant to the Cannabis Act , which came into effect on October 17, 2018 and regulates both the medical and recreational cannabis markets in Canada. The Company has also expanded to jurisdictions outside of Canada where cannabis and/or hemp is federally lawful, permissible and regulated, and the Company, through its subsidiaries, operates in the United States, Germany, and certain other global markets. Additionally, the Company produces, distributes and sells a range of other consumer products globally, including vaporizers; beauty, skincare, wellness and sleep products; and sports nutrition beverages. 2 . BASIS OF PRESENTATION These condensed interim consolidated financial statements have been presented in Canadian dollars and are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Canopy Growth has determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in Canadian dollars and our financial results are prepared and reviewed internally by management in Canadian dollars. Our condensed interim consolidated financial statements, and the financial information contained herein, are reported in thousands of Canadian dollars, except share and per share amounts or as otherwise stated. Certain information and footnote disclosures normally included in the audited annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted or condensed. These condensed interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 (the “Annual Report”) and have been prepared on a basis consistent with the accounting policies as described in the Annual Report. These condensed interim consolidated financial statements are unaudited and reflect adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods in accordance with U.S. GAAP. The results reported in these condensed interim consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for an entire fiscal year. The policies set out below are consistently applied to all periods presented, unless otherwise noted. Principles of consolidation The accompanying condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Information on the Company’s subsidiaries with noncontrolling interests is included in Note 20. Use of estimates The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates. New accounting policies Recently Adopted Accounting Pronouncements Income Taxes In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim 7 period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted ASU 2019-12 as of April 1, 2021. There was no material impact of adopting ASU 2019-12 on the condensed interim consolidated financial statements. Investments-Equity Securities In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) . ASU 2020-01 clarifies the interaction of accounting for the transition into and out of the equity method. The new standard also clarifies the accounting for measuring certain purchased options and forward contracts to acquire investments. The Company adopted ASU 2020-01 as of April 1, 2021. There was no impact of adopting ASU 2020-01 on the condensed interim consolidated financial statements. Accounting Guidance not yet adopted Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted after December 15, 2020. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2020-06 effective April 1, 2022. 3. ASSET IMPAIRMENT AND RESTRUCTURING COSTS In the three months ended June 30, 2021, the Company recorded charges related to operational changes resulting from the continuing strategic review of its business as a result of recent acquisition activities, which resulted in the closure of its Niagara-on-the-Lake, Ontario and Langley, British Columbia facilities. Additionally, the Company recognized costs associated with the closure of previously-identified Canadian production facilities in December 2020. In the three months ended September 30, 2021, the Company recognized incremental costs associated with the closure of certain of its Canadian production facilities in December 2020. In the three months ended December 31, 2021, the Company recorded charges primarily associated with adjustments related to changes in the estimated fair value of certain of the Company’s Canadian sites that were closed in December 2020. As a result, in the three and nine months ended December 31, 2021, the Company recognized asset impairment and restructuring costs of $ 36,439 and $ 128,198 , respectively, primarily representing the difference between the net book value of the associated long-lived assets and their estimated fair value. 4. CASH AND CASH EQUIVALENTS The components of cash and cash equivalents are as follows: December 31, March 31, 2021 2021 Cash $ 421,675 $ 436,588 Cash equivalents 193,471 718,065 $ 615,146 $ 1,154,653 8 5. SHORT-TERM INVESTMENTS The components of short-term investments are as follows: December 31, March 31, 2021 2021 Term deposits $ 354,745 $ 463,824 Asset-backed securities 63,197 16,342 Government securities 21,026 136,620 Commercial paper and other 368,916 527,777 $ 807,884 $ 1,144,563 The amortized cost of short-term investments at December 31, 2021 is $ 809,722 (March 31, 2021 – $ 1,145,364 ). 6. AMOUNTS RECEIVABLE, NET The components of amounts receivable, net are as follows: December 31, March 31, 2021 2021 Accounts receivable, net $ 82,554 $ 67,106 Indirect taxes receivable 6,553 8,281 Interest receivable 5,372 5,140 Other receivables 6,422 11,908 $ 100,901 $ 92,435 Included in the accounts receivable, net balance at December 31, 2021 is an allowance for doubtful accounts of $ 2,037 (March 31, 2021 – $ 1,411 ) . 7. INVENTORY The components of inventory are as follows: December 31, March 31, 2021 2021 Raw materials, packaging supplies and consumables $ 55,741 $ 55,554 Work in progress 166,425 223,652 Finished goods 143,584 88,773 $ 365,750 $ 367,979 In the three and nine months ended December 31, 2021, the Company recorded write-downs related to inventory in cost of goods sold of $ 11,811 and $ 104,662 (three and nine months ended December 31, 2020 – $ 23,836 and $ 48,167 ). 8. PREPAID EXPENSES AND OTHER ASSETS The components of prepaid expenses and other assets are as follows: December 31, March 31, 2021 2021 Prepaid expenses $ 31,292 $ 28,349 Deposits 19,200 18,316 Prepaid inventory 1,244 1,496 Other assets 34,531 19,071 $ 86,267 $ 67,232 9 9. OTHER FINANCIAL ASSETS The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments is calculated are included in Note 21. Foreign Exercise of Balance at currency options / Balance at March 31, Fair value translation Interest disposal December 31, Entity Instrument 2021 Additions changes adjustments income of shares 2021 TerrAscend Exchangeable Shares Exchangeable shares $ 385,000 $ - $ ( 166,000 ) $ - $ - $ - $ 219,000 TerrAscend Canada - October 2019 Term loan / debenture 10,240 - 750 - - - 10,990 TerrAscend Canada - March 2020 Term loan / debenture 56,330 - 550 - - - 56,880 Arise Bioscience Term loan / debenture 13,077 - 921 105 - - 14,103 TerrAscend - October 2019 Warrants 17,250 - ( 10,770 ) - - - 6,480 TerrAscend - March 2020 Warrants 152,910 - ( 73,830 ) - - - 79,080 TerrAscend - December 2020 Warrants 13,240 - ( 6,920 ) - - - 6,320 TerrAscend Option 10,600 - ( 4,600 ) - - - 6,000 Wana Option - 442,227 - 9,472 - - 451,699 Acreage Hempco 1 Debenture 27,448 - 4,023 197 ( 3,867 ) - 27,801 Other - at fair value through net income (loss) Various 14,887 6,457 ( 8,070 ) ( 138 ) - ( 92 ) 13,044 Other - classified as held for investment Loan receivable 7,185 - - - - ( 85 ) 7,100 $ 708,167 $ 448,684 $ ( 263,946 ) $ 9,636 $ ( 3,867 ) $ ( 177 ) $ 898,497 1 See Note 27 for information regarding Acreage Hempco . 10 Wana On October 14, 2021, the Company and Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, “Wana” and each, a “Wana Entity”) entered into definitive agreements (the “Wana Agreements”) providing the Company with the right, upon the occurrence or waiver (at the Company’s discretion) of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana, or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”), to acquire 100 % of the outstanding membership interests of Wana. Wana manufactures and sells gummies in the U.S. state of Colorado and licenses its intellectual property to partners, who manufacture, distribute, and sell Wana-branded gummies across the United States. The Wana Agreements are structured as three separate option agreements whereby the Company has a call option (the “Call Option”) to acquire 100 % of the membership interests in each Wana Entity. As consideration for entering into the Wana Agreements, the Company made an upfront cash payment (the “Upfront Payment”) in the aggregate amount of $ 368,067 (US$ 297,500 ). Upon the Company’s exercise of its right to acquire Wana, the Company will make payments equal to 15 % of the fair market value of Wana at the time the options are exercised (the “Call Option Payments”). As additional consideration for the right to acquire Wana, the Company expects to make additional deferred payments (the “Deferred Payments”) in respect of Wana as of the 2.5- and 5 -year anniversary of the Upfront Payment, computed based on a pre-determined contractual formula as follows: • Deferred Payment 1: 25 % of the amount computed as the estimated fair value of Wana at the 2.5 -year anniversary, less (i) the Upfront Payment, (ii) Wana debt, and (iii) certain other deductions; plus Wana cash, all at the 2.5-year anniversary. • Deferred Payment 2: 25 % of the amount computed as the estimated fair value of Wana at the 5 -year anniversary, less (i) the greater of (a) the Upfront Payment and (b) the estimated fair value of Wana at the 2.5-year anniversary, (ii) Wana debt, and (iii) certain other deductions, all at the 5-year anniversary; plus the difference in Wana cash between the 5-year and 2.5-year anniversaries. Payment of the Deferred Payments is not contingent upon the occurrence or waiver (at the Company’s discretion) of the Triggering Event or the exercise of the Call Option. At the Company’s option, the Call Option Payments and the Deferred Payments may be satisfied in cash, common shares or a combination thereof at the Company’s sole discretion. Until such time as the Company exercises its right to acquire Wana, the Company will have no economic or voting interest in Wana, the Company will not control Wana, and the Company and Wana will continue to operate independently. Upon initial recognition, the Company estimated the fair value of the Wana financial instrument to be $ 442,227 , consisting of (i) the Upfront Payment as noted above; and (ii) the present value of the estimated Deferred Payments, totaling $ 74,160 (see Note 15). The Wana financial instrument, in effect, represents an option to purchase 100 % of Wana for a payment equal to 15 % of Wana’s fair market value at the time the option is exercised. There was no change in the estimated fair value of the Wana financial instrument from initial recognition to December 31, 2021. Any subsequent changes in estimated fair value will be recognized in net income (loss). See Note 21 for additional details on how the fair value of the Wana financial instrument is calculated on a recurring basis. 11 10. PROPERTY, PLANT AND EQUIPMENT The components of property, plant and equipment are as follows: December 31, March 31, 2021 2021 Buildings and greenhouses $ 820,863 $ 651,166 Production and warehouse equipment 204,790 216,925 Leasehold improvements 86,307 106,837 Office and lab equipment 32,093 30,546 Land 23,410 34,747 Computer equipment 23,097 26,431 Right-of-use-assets Buildings and greenhouses 99,355 100,517 Production and warehouse equipment 182 530 Assets in process 25,496 129,428 1,315,593 1,297,127 Less: Accumulated depreciation ( 235,414 ) ( 222,590 ) $ 1,080,179 $ 1,074,537 Depreciation expense included in cost of goods sold for the three and nine months ended December 31, 2021 is $ 13,813 and $ 38,663 , respectively (three and nine months ended December 31, 2020 – $ 10,955 and $ 40,190 , respectively). Depreciation expense included in selling, general and administrative expenses for the three and nine months ended December 31, 2021 is $ 5,546 and $ 17,804 , respectively (three and nine months ended December 31, 2020 – $ 7,297 and $ 14,435 , respectively). 11. INTANGIBLE ASSETS The components of intangible assets are as follows: December 31, 2021 March 31, 2021 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Intellectual property $ 209,650 $ 157,206 $ 212,100 $ 168,655 Distribution channel 76,963 29,568 73,756 35,176 Software and domain names 30,517 13,855 27,836 18,149 Brands 21,675 8,143 21,812 8,894 Operating licenses 12,400 11,472 - - Amortizable intangibles in process 3,729 3,729 1,952 1,952 Total $ 354,934 $ 223,973 $ 337,456 $ 232,826 Indefinite lived intangible assets Acquired brands $ 104,780 $ 67,341 Operating licenses 10,000 8,000 Total intangible assets $ 338,753 $ 308,167 Amortization expense included in cost of goods sold for the three and nine months ended December 31, 2021 is $ 19 and $ 62 , respectively ( three and nine months ended December 31, 2020 – $ 99 and $ 62 , respectively). Amortization expense included in selling, general and administrative expenses for the three and nine months ended December 31, 2021 is $ 10,639 and $ 27,400 , respectively (three and nine months ended December 31, 2020 – $ 14,034 and $ 43,503 , respectively). 12 12. GOODWILL The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2020 $ 1,954,471 Foreign currency translation adjustments ( 65,117 ) Balance, March 31, 2021 $ 1,889,354 Purchase accounting allocations 112,939 Disposal of consolidated entities ( 5,245 ) Foreign currency translation adjustments ( 8,798 ) Balance, December 31, 2021 $ 1,988,250 13. OTHER ACCRUED EXPENSES AND LIABILITIES The components of other accrued expenses and liabilities are as follows: December 31, March 31, 2021 2021 Employee compensation $ 22,559 $ 47,237 Taxes and government fees 7,684 13,550 Professional fees 7,319 11,544 Other 38,445 28,482 $ 76,007 $ 100,813 14. DEBT The components of debt are as follows: December 31, March 31, Maturity Date 2021 2021 Convertible senior notes at 4.25 % interest with semi-annual interest payments July 15, 2023 Principal amount $ 600,000 $ 600,000 Accrued interest 12,042 5,664 Non-credit risk fair value adjustment 9,240 109,710 Credit risk fair value adjustment ( 54,240 ) ( 27,960 ) 567,042 687,414 Convertible debentures September 10, 2025 31,689 - Accretion debentures September 10, 2025 7,478 - Credit facility March 18, 2026 901,003 891,677 Other revolving debt facility, loan, and financings 3,155 3,872 1,510,367 1,582,963 Less: current portion ( 15,702 ) ( 9,827 ) Long-term portion $ 1,494,665 $ 1,573,136 Credit Facility On March 18, 2021, the Company entered into a credit agreement (the “Credit Agreement”) providing for a five-year, first lien senior secured term loan facility in an aggregate principal amount of US$ 750,000 (the “Credit Facility”). The Company also has the ability to obtain up to an additional US$ 500,000 of incremental senior secured debt pursuant to the Credit Agreement. The Credit Facility has no principal payments, matures on March 18, 2026, has a coupon of LIBOR plus 8.50 % and is subject to a LIBOR floor of 1.00 %. In the event that LIBOR can no longer be adequately ascertained or is no longer available, an alternative rate as permitted under the Credit Agreement will be used. The Company’s obligations under the Credit Facility are guaranteed by material wholly-owned Canadian and U.S. subsidiaries of the Company. The Credit Facility is secured by substantially all of these assets, including material real property, of the borrowers and each of the guarantors. The Credit Agreement contains representations and warranties, and affirmative and negative covenants, including a financial covenant requiring minimum liquidity of US$ 200,000 at the end of each fiscal quarter. 13 The proceeds from the Credit Facility were $ 893,160 , and the carrying amount is reflected net of financing costs. Convertible Notes On June 20, 2018, the Company issued convertible senior notes (the “Notes”) with an aggregate principal amount of $ 600,000 . The Notes bear interest at a rate of 4.25 % per annum, payable semi-annually on January 15th and July 15th of each year commencing from January 15, 2019 . The Notes will mature on July 15, 2023 . The Notes are subordinated in right of payment to any existing and future senior indebtedness, including any indebtedness under the revolving debt facility with FCC (as defined below). The Notes will rank senior in right of payment to any future subordinated borrowings. The Notes are effectively junior to any secured indebtedness and the Notes are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries. Holders of the Notes may convert the Notes at their option at any time from January 15, 2023 to the maturity date. The Notes will be convertible, at the holder’s option, at a conversion rate of 20.7577 common shares for every $ 1 principal amount of Notes (equal to an initial conversion price of approximately $ 48.18 per common share), subject to adjustments in certain events. In addition, the holder has the right to exercise the conversion option from September 30, 2018 to January 15, 2023, if (i) the market price of the Company common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130 % of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “Measurement Period”) in which the trading price per $ 1 principal amount of the Notes for each trading day in the Measurement Period was less than 98 % of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the Notes are called for redemption or (iv) upon occurrence of certain corporate events (a “Fundamental Change”). A Fundamental Change occurred upon completion of the investment by Constellation Brands, Inc. (“CBI”) in the Company in November 2018, and no holders of Notes surrendered any portion of their Notes in connection therewith . The Company may, upon conversion by the holder, elect to settle in either cash, common shares, or a combination of cash and common shares, subject to certain circumstances. Under the terms of the indenture, if a Fundamental Change occurs and a holder elects to convert its Notes from and including on the date of the Fundamental Change up to, and including, the business day immediately prior to the Fundamental Change repurchase date, the Company may be required to increase the conversion rate for the Notes so surrendered for conversion by a number of additional common shares. Prior to July 20, 2021, the Company could not redeem the Notes except in the event of certain changes in Canadian tax law. On or after July 20, 2021 , the Company could redeem for cash, subject to certain conditions, any or all of the Notes, at its option, if the last reported sales price of the Company’s common shares for at least 20 trading days during any 30 consecutive trading day period ending within 5 trading days immediately preceding the date on which the Company provides notice of redemption exceeds 130 % of the conversion price on each applicable trading day. The Company may also redeem the Notes, if certain tax laws related to Canadian withholding tax change subject to certain further conditions. The redemption of Notes in either case shall be at a redemption price equal to 100 % of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. For accounting purposes, the equity conversion feature did not meet the equity classification guidance, therefore the Company elected the fair value option under ASC 825 – Financial Instruments (“ASC 825”). The Notes were initially recognized at fair value on the balance sheet. All subsequent changes in fair value, excluding the impact of the change in fair value related to the Company’s own credit risk are recorded in other income (expenses), net. The changes in fair value related to the Company’s own credit risk are recorded through other comprehensive income (loss). The overall change in fair value of the Notes during the three and nine months ended December 31, 2021, was a decrease of $ 16,806 and $ 120,372 , respectively (three and nine months ended December 31, 2020, an increase of $ 105,588 and $ 177,588 , respectively), which included contractual interest of $ 6,444 and $ 19,128 (three and nine months ended December 31, 2020, interest of $ 6,588 and $ 19,338 , respectively). Refer to Note 21 for additional details on how the fair value of the Notes is calculated. Supreme Cannabis Convertible Debentures and Accretion Debentures On October 19, 2018, Supreme Cannabis (as defined below) entered into an indenture with Computershare Trust Company of Canada (the “Trustee”) pursuant to which Supreme Cannabis issued 6.0 % senior unsecured convertible debentures (the “Supreme Debentures”) for gross proceeds of $ 100,000 . On September 9, 2020, Supreme Cannabis and the Trustee entered into a supplemental indenture to effect certain amendments to the Supreme Debentures, which included among other things: (i) the cancellation of $ 63,500 of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8 % per annum; (iii) the extension of the maturity date to September 10, 2025 ; and (iv) a reduction in the conversion price to $ 0.285 . In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the “Accretion Debentures”). The principal amount began at $nil and accretes at a rate of 11.06 % per annum based on the remaining principal amount of the Supreme Debentures of $ 36,500 to a maximum of $ 13,500 , compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. The Accretion Debentures are payable in cash, but do not bear cash interest and are not 14 convertible into Supreme Shares (as defined below) . The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0 % per month over the 24 months prior to maturity. As a result of the Supreme Arrangement (as defined below), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled. In connection with the Supreme Arrangement, the Company, Supreme Cannabis and the Trustee entered into a supplemental indenture whereby the Company agreed to issue common shares upon conversion of any Supreme Debenture. In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures. Prior to September 9, 2023, the Supreme Debentures are not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Convertible Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full. Other revolving debt facility, loans, and financings On August 13, 2019, the Company, through its wholly owned subsidiary, Tweed Inc., entered into a $ 40,000 revolving debt facility with Farm Credit Canada (“FCC”). The new facility replaces the previous loans with FCC and is secured by the Company’s property in Niagara-on-the-Lake. The extinguishment of $ 4,912 in previous FCC debt resulted in no gain or loss. The current outstanding balance of the FCC debt facility is $nil (March 31, 2021 – $nil) with an interest rate of 3.45 %, or FCC prime rate plus 1.0 % . The facility expires on September 3, 2024. The revolving debt facility with FCC is secured by a first charge on the properties in Niagara-on-the-Lake, Ontario, a corporate guarantee from the Company, and a general corporate security agreement . 15. OTHER LIABILITIES The components of other liabilities are as follows: As at December 31, 2021 As at March 31, 2021 Current Long-term Total Current Long-term Total Lease liabilities $ 38,684 $ 104,300 $ 142,984 $ 42,061 $ 94,164 $ 136,225 Acquisition consideration and other investment related liabilities 4,078 83,681 87,759 16,577 7,808 24,385 Refund liability 6,046 - 6,046 6,441 - 6,441 Settlement liabilities and other 30,892 7,637 38,529 41,349 5,268 46,617 $ 79,700 $ 195,618 $ 275,318 $ 106,428 $ 107,240 $ 213,668 On October 14, 2021, upon entering into the Wana Agreements, the Company recognized the present value of the estimated Deferred Payments associated with the Wana financial instrument within acquisition consideration and other investment related liabilities, in the amount of $ 74,160 (see Note 9). 15 16. REDEEMABLE NONCONTROLLING INTEREST The net changes in the redeemable noncontrolling interests are as follows: Vert Mirabel BioSteel Total As at March 31, 2021 $ 11,500 $ 123,800 $ 135,300 Net loss attributable to redeemable noncontrolling interest ( 2,401 ) ( 10,699 ) ( 13,100 ) Adjustments to redemption amount 2,401 ( 50,792 ) ( 48,391 ) Redemption of redeemable noncontrolling interest - ( 5,109 ) ( 5,109 ) As at December 31, 2021 $ 11,500 $ 57,200 $ 68,700 Vert Mirabel BioSteel Total As at March 31, 2020 $ 20,250 $ 49,500 $ 69,750 Net loss attributable to redeemable noncontrolling interest ( 5,593 ) ( 4,287 ) ( 9,880 ) Adjustments to redemption amount 5,543 45,687 51,230 As at December 31, 2020 $ 20,200 $ 90,900 $ 111,100 17. SHARE CAPITAL CANOPY GROWTH Authorized An unlimited number of common shares. (i) Equity financings There were no equity financings during the nine months ended December 31, 2021 (nine months ended December 31, 2020 - no ne). (ii) Other issuances of common shares During the nine months ended December 31, 2021, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Acquisition of Supreme Cannabis 9,013,400 $ 260,668 $ - Completion of acquisition milestones 1,295,285 29,276 ( 29,721 ) Other issuances 351,252 6,630 ( 405 ) Total 10,659,937 $ 296,574 $ ( 30,126 ) During the nine months ended December 31, 2020, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Completion of acquisition milestones 1,149,086 $ 21,531 $ ( 13,009 ) Other issuances 412,417 14,135 ( 14,712 ) Total 1,561,503 $ 35,666 $ ( 27,721 ) 16 (iii) Warrants Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2021 1 127,073,136 $ 58.33 $ 2,568,438 Supreme Cannabis warrants 1,265,742 25.61 13,350 Expiry of warrants ( 145,831 ) 32.61 - Balance outstanding at December 31, 2021 1 128,193,047 $ 58.04 $ 2,581,788 1 This balance excludes the Tranche C Warrants (as defined below), which represent a derivative liability and have nominal value. See Note 27. Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2020 1 146,299,443 $ 52.44 $ 2,638,951 Exercise of warrants ( 18,876,901 ) 12.98 ( 70,266 ) Expiry of warrants ( 343,380 ) 41.49 - Balance outstanding at December 31, 2020 1 127,079,162 $ 58.30 $ 2,568,685 1 This balance excludes the Tranche C Warrants (as defined below), which represent a derivative liability and have nominal value. See Note 27. 18. SHARE-BASED COMPENSATION CANOPY GROWTH CORPORATION SHARE-BASED COMPENSATION PLAN Canopy Growth's eligible employees participate in a share-based compensation plan as noted below. On September 21, 2020, the Company’s shareholders approved amendments to the Company’s Amended and Restated Omnibus Incentive Plan (as amended and restated, the “Omnibus Plan”) pursuant to which the Company can issue share-based long-term incentives. The Omnibus Plan approved by the shareholders extended the maximum term of each Option (as defined below) to be granted by the Company to ten years from the date of grant rather than six years from the date of grant. On May 27, 2021, the Board of Directors of the Company approved certain amendments to the Omnibus Plan in order to reduce the maximum number of shares available for issuance under the Omnibus Plan from 15 % of the issued and outstanding shares to 10 % of the issued and outstanding shares from time to time less the number of shares issuable pursuant to other security-based compensation arrangements of the Company. All directors, officers, employees and independent contractors of the Company are eligible to receive awards of common share purchase options (“Options”), restricted share units (“RSUs”), performance share units (“PSUs”), deferred share units, stock appreciation rights, performance awards, or other shares-based awards (collectively, the “Awards”) under the Omnibus Plan. The maximum number of common shares reserved for Awards is 39,415,800 at December 31, 2021. As of December 31, 2021, the only Awards issued have been Options, RSUs and PSUs under the Omnibus Plan. The Omnibus Plan is administered by the Corporate Governance, Compensation and Nominating Committee of the Company (the “CGC&N Committee”) which establishes exercise prices, at not less than the market price at the date of grant, and expiry dates. Options under the Omnibus Plan generally become exercisable in increments with 1/3 being exercisable on each of the first, second and third anniversaries from the date of grant, with expiry dates set at ten years from issuance, subject to the capacity of the CGC&N Committee pursuant to the Omnibus Plan to provide for an expiry date in an award agreement for the grant of options, which is less than ten years from issuance. The CGC&N Committee has the discretion to amend general vesting provisions and the term of any award, subject to limits contained in the Omnibus Plan. Under the Company’s Employee Share Purchase Plan (the “Purchase Plan”) the aggregate number of common shares that may be issued is 600,000 , and the maximum number of common shares which may be issued in any one fiscal year shall not exceed 300,000 . For the three and nine months ended December 31, 2021, 61,103 common shares were issued under the Purchase Plan. 17 The following is a summary of the changes in the Options outstanding during the nine months ended December 31, 2021: Options issued Weighted average exercise price Balance outstanding at March 31, 2021 17,704,311 $ 36.79 Options granted 2,528,021 17.42 Replacement options issued as a result of the acquisition of Supreme Cannabis 140,159 80.53 Options exercised ( 421,476 ) 12.65 Options forfeited ( 2,213,825 ) 39.70 Balance outstanding at December 31, 2021 17,737,190 $ 34.17 The following is a summary of the Options as at December 31, 2021: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices December 31, 2021 (years) December 31, 2021 (years) $0.06 - $24.62 3,789,682 4.31 1,263,512 2.14 $24.63 - $33.53 4,153,283 3.49 2,331,110 2.89 $33.54 - $36.80 3,229,461 2.51 3,229,461 2.51 $36.81 - $42.84 2,857,506 3.19 2,622,583 2.87 $42.85 - $171.54 3,707,258 3.13 2,921,964 3.06 17,737,190 3.36 12,368,630 2.75 At December 31, 2021, the weighted average exercise price of Options outstanding and Options exercisable was $ 34.17 and $ 38.05 , respectively (March 31, 2021 – $ 36.79 and $ 36.97 , respectively). The Company recorded $ 3,696 and $ 22,038 , respectively, in share-based compensation expense related to Options and Purchase Plan shares issued to employees and contractors for the three and nine months ended December 31, 2021 (three and nine months ended December 31, 2020 – $ 16,663 and $ 54,516 , respectively). The share-based compensation expense for the nine months ended December 31, 2021 includes an amount related to 1,559,413 Options being provided in exchange for services which are subject to performance conditions (for the nine months ended December 31, 2020 – 2,112,745 ). The Company issued replacement options to employees in relation to the acquisition of Supreme Cannabis (Note 26) and during the three and nine months ended December 31, 2021, recorded share-based compensation expense of $nil and $ 823 , respectively. The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2021 and 2020, on their measurement date by applying the following assumptions: December 31, December 31, 2021 2020 Risk-free interest rate 1.21 % 0.49 % Expected life of options (years) 3 - 5 5 - 7 Expected volatility 75 % 73 % Expected forfeiture rate 18 % 17 % Expected dividend yield nil nil Black-Scholes value of each option $ 7.55 $ 23.53 Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that Options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the Options. During the nine months ended December 31, 2021, 421,476 Options were exercised ranging in price from $ 0.06 to $ 36.34 for gross proceeds of $ 5,455 (for the nine months ended December 31, 2020 – 3,176,977 Options were exercised ranging in price from $ 0.06 to $ 36.34 for gross proceeds of $ 37,999 ). 18 For the three and nine months ended December 31, 2021, the Company recorded $ 1,950 and $ 7,935 , respectively, in share-based compensation expense related to RSUs and PSUs (for the three and nine months ended December 31, 2020 – $ 2,685 and $ 8,870 , respectively). The following is a summary of the changes in the Company’s RSUs and PSUs during the nine months ended December 31, 2021: Number of RSUs and PSUs Balance outstanding at March 31, 2021 753,310 RSUs and PSUs granted 564,150 RSUs and PSUs released ( 197,316 ) RSUs and PSUs cancelled and forfeited ( 201,000 ) Balance outstanding at December 31, 2021 919,144 During the three and nine months ended December 31, 2021, the Company recorded $971 and $4,376, respectively, in share-based compensation expense (recovery) related to acquisition milestones (for the three and nine months ended December 31, 2020 – $(21) and $5,857, respectively). During the three and nine months ended December 31, 2021, 419,884 and 1,295,285 , common shares, respectively, were released on completion of acquisition milestones (during the three and nine months ended December 31, 2020 – nil and 1,149,086 , respectively). At December 31, 2021, there were up to 256,057 common shares to be issued on the completion of acquisition and asset purchase milestones. In certain cases, the number of common shares to be issued is based on the volume weighted average share price at the time the milestones are met. The number of common shares has been estimated assuming the milestones were met at December 31, 2021. The number of common shares excludes common shares that are to be issued on July 4, 2023 to the previous shareholders of Spectrum Colombia S.A.S. and Canindica Capital Ltd. based on the fair market value of the Company’s Latin American business on that date. BioSteel share-based payments On October 1, 2019, the Company purchased 72 % of the outstanding shares of BioSteel Sports Nutrition Inc. (“BioSteel”). BioSteel has a stock option plan under which non-transferable options to purchase common shares of BioSteel may be granted to directors, officers, employees, or independent contractors of the BioSteel. As at December 31, 2021, BioSteel had 1,545,300 (March 31, 2021 – 1,581,000 ) options outstanding which vest in equal tranches over a 5 -year period. In determining the amount of share-based compensation related to these options, BioSteel used the Black-Scholes option pricing model to establish the fair value of options on their measurement date. The Company recorded $ 160 and $ 684 of share-based compensation expense related to the BioSteel options during the three and nine months ended December 31, 2021, respectively, with a corresponding increase in noncontrolling interest (three and nine months ended December 31, 2020 – $ 256 and $ 918 , respectively). RIV Capital Inc. (“RIV Capital”) share-based payments For the three and nine months ended December 31, 2020, the Company recorded $ 381 and $ 2,471 , respectively, in share-based compensation expense related to its former subsidiary, RIV Capital. The Company disposed of its investment in RIV Capital on February 23, 2021. 19. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2021 $ ( 28,246 ) $ ( 5,994 ) $ ( 34,240 ) Other comprehensive income (loss) ( 18,767 ) 26,280 7,513 As at December 31, 2021 $ ( 47,013 ) $ 20,286 $ ( 26,727 ) 19 Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2020 $ 126,723 $ 94,176 $ 220,899 Other comprehensive loss ( 110,932 ) ( 82,560 ) ( 193,492 ) As at December 31, 2020 $ 15,791 $ 11,616 $ 27,407 20. NONCONTROLLING INTERESTS The net change in the noncontrolling interests is as follows: Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2021 $ - $ 1,658 $ 3,051 $ 4,709 Comprehensive loss ( 2,401 ) ( 10,699 ) ( 1,207 ) ( 14,307 ) Net loss attributable to redeemable noncontrolling interest 2,401 10,699 - 13,100 Share-based compensation - 684 - 684 As at December 31, 2021 $ - $ 2,342 $ 1,844 $ 4,186 Canopy Rivers Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2020 $ 211,086 $ 7,132 $ 489 $ 3,051 $ 221,758 Comprehensive loss 4,060 ( 8,956 ) ( 4,287 ) - ( 9,183 ) Net loss attributable to redeemable noncontrolling interest - 5,593 4,287 - 9,880 Share-based compensation 2,471 - 918 - 3,389 Ownership changes 1,521 175 - - 1,696 Warrants 250 - - - 250 As at December 31, 2020 $ 219,388 $ 3,944 $ 1,407 $ 3,051 $ 227,790 21. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value measurements are made using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value: • Level 1 – defined as observable inputs such as quoted prices in active markets; • Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and • Level 3 – defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The fair value measurement is categorized in its entirety by reference to its lowest level of significant input. The Company records cash, accounts receivable, interest receivable and accounts payable, and other accrued expenses and liabilities at cost. The carrying values of these instruments approximate their fair value due to their short-term maturities. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Assets and liabilities recognized or disclosed at fair value on a nonrecurring basis may include items such as property, plant and equipment, goodwill and other intangible assets, equity and other investments and other assets. We determine the fair value of these items using Level 3 inputs, as described in the related sections below. 20 The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted prices Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total December 31, 2021 Assets: Short-term investments $ 807,884 $ - $ - $ 807,884 Restricted short-term investments 12,208 - - 12,208 Other financial assets 554 - 890,843 891,397 Liabilities: Convertible senior notes - 567,042 - 567,042 Liability arising from Acreage Arrangement - - 103,000 103,000 Warrant derivative liability - - 37,491 37,491 March 31, 2021 Assets: Short-term investments $ 1,144,563 $ - $ - $ 1,144,563 Restricted short-term investments 11,332 - - 11,332 Other financial assets 254 - 700,728 700,982 Liabilities: Convertible senior notes - 687,414 - 687,414 Liability arising from Acreage Arrangement - - 600,000 600,000 Warrant derivative liability - - 615,575 615,575 The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Convertible senior notes Convertible note pricing model Quoted prices in over-the-counter broker market 21 The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return model Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value Number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend Exchangeable Shares, TerrAscend Option Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - October 2019, March 2020 Black-Sholes option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value TerrAscend warrants - December 2020 Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Arise Bioscience term loan, TerrAscend Canada term loan - Discounted cash flow Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value October 2019, March 2020 Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument Monte Carlo simulation model Probability of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Wana Increase or decrease in volatility will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of Canopy Growth share price Increase or decrease in volatility will result in an increase or decrease in fair value BioSteel redeemable NCI Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value Vert Mirabel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value During the nine months ended December 31, 2021 and December 31, 2020, there were no transfers of amounts between levels . 22 22. REVENUE Revenue is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Canadian recreational cannabis net revenue Business-to-business 1 $ 33,282 $ 43,129 $ 117,902 $ 120,286 Business-to-consumer 14,477 20,224 48,473 48,263 47,759 63,353 166,375 168,549 Canadian medical cannabis net revenue 2 12,919 13,947 39,504 41,745 60,678 77,300 205,879 210,294 International and other revenue C 3 9,675 17,642 33,005 46,567 Other 12,624 8,886 32,357 20,543 22,299 26,528 65,362 67,110 Global cannabis net revenue 82,977 103,828 271,241 277,404 Other consumer products Storz & Bickel 25,205 24,147 63,786 63,103 This Works 10,730 10,907 26,308 24,789 BioSteel 16,974 7,348 31,147 14,918 Other 5,086 6,298 16,073 17,996 Other consumer products revenue 57,995 48,700 137,314 120,806 Net revenue $ 140,972 $ 152,528 $ 408,555 $ 398,210 1 Canadian recreational business-to-business net revenue during the three and nine months ended December 31, 2021 reflects excise taxes of $ 12,754 and $ 43,501 , respectively (three and nine months ended December 31, 2020 – $ 15,977 and $ 37,423 , respectively). 2 Canadian medical cannabis net revenue for the three and nine months ended December 31, 2021 reflects excise taxes of $ 1,298 and $ 4,039 , respectively (three and nine months ended December 31, 2020 – $ 1,402 and $ 4,190 , respectively). The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $ 1,000 and $ 4,000 for the three and nine months ended December 31, 2021, respectively (three and nine months ended December 31, 2020 – $ 3,750 and $ 10,900 , respectively). As of December 31, 2021, the liability for estimated returns and price adjustments was $ 6,046 (March 31, 2021 – $ 6,441 ). 23 23. OTHER INCOME (EXPENSE), NET Other income (expense), net is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Fair value changes on other financial assets $ ( 68,666 ) $ 281,359 $ ( 263,946 ) $ 385,219 Fair value changes on liability arising from Acreage Arrangement 59,000 ( 303,000 ) 497,000 ( 249,849 ) Fair value changes on convertible senior notes 606 ( 75,498 ) 81,342 ( 107,778 ) Fair value changes on warrant derivative liability 67,282 ( 193,998 ) 578,084 ( 93,455 ) Fair value changes on acquisition related contingent consideration and other 712 ( 3,066 ) 544 39,803 Interest income 1,575 7,310 6,977 19,078 Interest expense ( 26,408 ) ( 1,030 ) ( 77,618 ) ( 3,708 ) Foreign currency gain (loss) 990 710 2,902 ( 10,290 ) Loss on disposal of consolidated entity - - ( 1,653 ) - Other income (expense), net ( 809 ) ( 3,354 ) ( 12,863 ) ( 126 ) $ 34,282 $ ( 290,567 ) $ 810,769 $ ( 21,106 ) 24. INCOME TAXES There have been no material changes to income tax matters in connection with normal course operations during the nine months ended December 31, 2021. The Company is subject to income tax in numerous jurisdictions with varying income tax rates. During the most recent period ended and the fiscal year to date, there were no material changes to the statutory income tax rates in the taxing jurisdictions where the majority of the Company’s income for tax purposes was earned, or where its temporary differences or losses are expected to be realized or settled. Although statutory income tax rates remain stable, the Company’s effective income tax rate may fluctuate, arising as a result of the Company’s evolving footprint, discrete transactions and other factors that, to the extent material, are disclosed in these financial statements. The Company continues to believe that the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the reporting period in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company’s estimate, such difference will impact the Company’s income taxes in the reporting period during which such determination is made. 24 25. EARNINGS (LOSS) PER SHARE Basic and diluted earnings (loss) per share are calculated using the following numerators and denominators: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Basic (loss) earnings per share computation Net (loss) income attributable to common shareholders of Canopy Growth $ ( 108,925 ) $ ( 904,380 ) $ 272,435 $ ( 1,044,942 ) Weighted average number of common shares outstanding 393,818,282 372,908,767 390,423,083 369,418,037 Basic (loss) earnings per share $ ( 0.28 ) $ ( 2.43 ) $ 0.70 $ ( 2.83 ) Diluted (loss) earnings per share computation Net (loss) income used in the computation of basic (loss) earnings per share $ ( 108,925 ) $ ( 904,380 ) $ 272,435 $ ( 1,044,942 ) Numerator adjustments for diluted (loss) earnings per share: Adjustment to net loss attributable to noncontrolling interests and redeemable noncontrolling interest - - ( 13,100 ) - Removal of fair value changes on convertible senior notes - - ( 81,342 ) - Net (loss) income used in the computation of diluted (loss) earnings per share $ ( 108,925 ) $ ( 904,380 ) $ 177,993 $ ( 1,044,942 ) Weighted average number of common shares outstanding used in the computation of basic (loss) earnings per share 393,818,282 372,908,767 390,423,083 369,418,037 Denominator adjustments for diluted (loss) earnings per share: Dilutive impact of assumed exercise or conversion of: Convertible senior notes - - 12,454,620 - Redeemable noncontrolling interest - - 4,528,898 - Stock options - - 745,700 - Other securities - - 2,834,501 - Weighted average number of common shares for computation of diluted (loss) earnings per share 393,818,282 372,908,767 410,986,802 369,418,037 Diluted (loss) earnings per share 1 $ ( 0.28 ) $ ( 2.43 ) $ 0.43 $ ( 2.83 ) 1 In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive . 25 26. ACQUISITIONS The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the nine months ended December 31, 2021: Ace Supreme Valley Cannabis (i) (ii) Other Total Cash and cash equivalents $ 1,544 $ 41,306 $ 1,227 $ 44,077 Inventory 878 33,426 428 34,732 Other current assets 2,249 15,145 305 17,699 Property, plant and equipment 105 187,407 1,510 189,022 Intangible assets Brands 14,000 24,600 - 38,600 Distribution channel - 3,500 - 3,500 Operating licenses - 12,400 2,000 14,400 Goodwill 39,152 66,524 7,263 112,939 Accounts payable and other accrued expenses and liabilities ( 1,724 ) ( 13,056 ) - ( 14,780 ) Debt and other liabilities - ( 88,324 ) ( 1,037 ) ( 89,361 ) Deferred income tax liabilities ( 1,899 ) ( 3,260 ) ( 540 ) ( 5,699 ) Net assets acquired $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Consideration paid in shares - 260,668 4,052 264,720 Replacement options - 629 - 629 Replacement warrants - 13,350 - 13,350 Other consideration 2,469 4,937 - 7,406 Total consideration $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Less: Cash and cash equivalents acquired ( 1,544 ) ( 41,306 ) ( 1,227 ) ( 44,077 ) Net cash outflow (inflow) $ 50,292 $ ( 41,222 ) $ 5,877 $ 14,947 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for each acquisition. Goodwill arose in these acquisitions because the cost of acquisition included a control premium. In addition, the consideration paid for the combination reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. No ne of the goodwill arising on these acquisitions is expected to be deductible in the computation of income for tax purposes. (i) Ace Valley On April 1, 2021 , the Company entered into a share purchase agreement (the “AV Share Purchase Agreement”) with Tweed Inc., AV Cannabis Inc. (“Ace Valley”), and the shareholders of Ace Valley (the “AV Vendors”) pursuant to which the Company indirectly acquired 100 % of the issued and outstanding shares of Ace Valley for cash consideration of $ 51,836 . Ace Valley is an Ontario-based cannabis brand with a focus on premium, ready-to-enjoy products including vapes, pre-roll joints and gummies. Pursuant to the terms of the AV Share Purchase Agreement, the Company may be required to make certain earn-out payments to the AV Vendors, which may result in an additional cash payment or the issuance of common shares, subject to the fulfillment of certain conditions by April 1, 2023. This represents liability-classified contingent consideration. Management has estimated the fair value of this consideration to be $ 2,469 by assessing the probability and timing of the fulfillment of the specified conditions and discounting the expected cash outflows to present value. Due to the timing of this acquisition, the purchase price allocation for the acquisition of Ace Valley is provisional. The fair value assigned to the consideration paid, intangible assets and net assets acquired is based on management’s best estimate using the information currently available and may be revised by the Company as additional information is received. (ii) Supreme Cannabis On June 22, 2021 , the Company and the Supreme Cannabis Company, Inc. (“Supreme Cannabis”) completed an arrangement (the “Supreme Arrangement”) pursuant to which the Company acquired 100 % of the issued and outstanding common shares of Supreme Cannabis (the “Supreme Shares”). Supreme Cannabis is a producer of recreational, wholesale and medical cannabis products, with a diversified portfolio of distinct cannabis companies, products and brands. Pursuant to the Supreme Arrangement, the Company issued 9,013,400 common shares with a fair value on closing of $ 260,668 and made a cash payment of $ 84 to former Supreme Cannabis shareholders in consideration for their Supreme Shares. 26 The Company also assumed the obligation to issue 1,265,742 common shares upon the exercise of outstanding warrants of Supreme Cannabis and issued 140,159 replacement options. The fair value of the obligation upon the exercise of the outstanding warrants of Supreme Cannabis was estimated to be $ 13,350 using a Black-Scholes model. The replacement options’ fair value totaled $ 1,452 , calculated using a Black-Scholes model, of which $ 629 was included in consideration paid as it related to pre-combination services and the residual $ 823 fair value was recognized immediately in share-based compensation expense after the completion of the acquisition. On June 22, 2021, Supreme Cannabis had convertible debentures outstanding with a principal amount of $ 27,045 which were convertible into 94,895,649 Supreme Shares. As a result of the acquisition the conversion feature was adjusted in accordance with an exchange ratio of 0.011659 . The fair value of these convertible debentures on June 22, 2021 was estimated to be $ 36,593 , of which $ 4,937 was allocated to the conversion feature and $ 31,656 to the debt component. Due to the timing of this acquisition, the purchase price allocation for the acquisition of Supreme Cannabis is provisional. The fair value assigned to the consideration paid, intangible assets and net assets acquired is based on management’s best estimate using the information currently available and may be revised by the Company as additional information is received. 27. ACREAGE ARRANGEMENT AND AMENDMENTS TO CBI INVESTOR RIGHTS AGREEMENT AND WARRANTS Acreage Arrangement On September 23, 2020, the Company and Acreage Holdings, Inc. (“Acreage”) entered into a second amendment (the “Acreage Amending Agreement”) to the arrangement agreement (the “Acreage Arrangement Agreement”) between the Company and Acreage dated April 18, 2019, as amended on May 15, 2019, and implemented an amended and restated plan of arrangement (the “Acreage Amended Arrangement”). The Acreage Amended Arrangement provides for, among other things, the following: • Following the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event and subject to the satisfaction or waiver of the conditions set out in the Acreage Arrangement Agreement (as modified in connection with the Acreage Amending Agreement), Canopy Growth will acquire all of the issued and outstanding Class E subordinated voting shares (the “Fixed Shares”) based on an amended exchange ratio equal to 0.3048 of a common share to be received for each Fixed Share held. The foregoing exchange ratio for the Fixed Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if, among other things, Acreage issues greater than the permitted number of Fixed Shares; • Upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event, Canopy Growth will have the right exercisable for a period of 30 days, to acquire all of the issued and outstanding Class D subordinated voting shares (the “Floating Shares”) for cash or common shares or a combination thereof, in Canopy Growth’s sole discretion at a price equal to the 30-day volume weighted average trading price of the Floating Shares on the Canadian Securities Exchange, subject to a minimum call price of US$ 6.41 per Floating Share. The foregoing exchange ratio for the Floating Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if Acreage issues greater than the permitted number of Floating Shares. The acquisition of the Floating Shares, if acquired, will take place concurrently with the closing of the acquisition of the Fixed Shares; • Immediately prior to the acquisition of the Fixed Shares, each issued and outstanding Class F multiple voting share will automatically be exchanged for one Fixed Share and thereafter be acquired by Canopy Growth upon the same terms and conditions as the acquisition of the Fixed Shares; • If the occurrence or waiver of the Triggering Event does not occur by September 23, 2030, Canopy Growth’s rights to acquire both the Fixed Shares and the Floating Shares will terminate; • Upon implementation of the Acreage Amended Arrangement, Canopy Growth made a cash payment to the shareholders of Acreage and holders of certain convertible securities in the aggregate amount of US$ 37,500 ($ 49,849 ); and • Acreage is only permitted to issue an aggregate of up to 32,700,000 Fixed Shares and Floating Shares. At December 31, 2021, the right and the obligation (the “Acreage financial instrument”) to acquire the Fixed Shares represents a financial liability of $ 103,000 (March 31, 2021 – $ 600,000 ), as the estimated fair value of the Acreage business is less than the estimated fair value of the consideration to be provided upon the exercise of the Acreage financial instrument. Fair value changes of $ 59,000 and $ 497,000 were recognized in other income (expense), net in the three and nine months ended December 31, 2021, respectively (three and nine months ended December 31, 2020 – $( 303,000 ) and $( 249,849 ), respectively) (see Note 23). The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 21 for additional details on how the fair value of the Acreage financial instrument is calculated on a recurring basis. From a measurement perspective, the Company has elected the fair value option under ASC 825. 27 In connection with the Acreage Amended Arrangement, on September 23, 2020, an affiliate of the Company advanced US$ 50,000 ($ 66,995 ) to Universal Hemp, LLC, a wholly-owned subsidiary of Acreage (“Acreage Hempco”) pursuant to a secured debenture (“Debenture”). In accordance with the terms of the Debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. The Debenture bears interest at a rate of 6.1 % per annum, matures on September 23, 2030, or such earlier date in accordance with the terms of the Debenture, and all interest payments made pursuant to the Debenture are payable in cash by Acreage Hempco. The Debenture is not convertible and is not guaranteed by Acreage. The amount advanced on September 23, 2020 pursuant to the Debenture has been recorded in other financial assets (see Note 9), and the Company has elected the fair value option under ASC 825 (see Note 21). At December 31, 2021, the estimated fair value of the Debenture issued to an affiliate of the Company by Acreage Hempco was $ 27,801 (March 31, 2021 – $ 27,448 ), measured using a discounted cash flow model (see Note 21). Refer to Note 9 for details on fair value changes, foreign currency translation adjustment, and interest received during the nine months ended December 31, 2021. An additional US$ 50,000 may be advanced pursuant to the Debenture subject to the satisfaction of certain conditions by Acreage Hempco. Amendment to the CBI Investor Rights Agreement and warrants On April 18, 2019, certain wholly-owned subsidiaries of CBI and Canopy Growth entered into a second amended and restated investor rights agreement and a consent agreement. In connection with these agreements, on June 27, 2019, Canopy Growth (i) extended the term of the first tranche of warrants, which allow CBI to acquire 88.5 million additional shares of Canopy Growth for a fixed price of $ 50.40 per share (the “Tranche A Warrants”), to November 1, 2023 ; and (ii) replaced the second tranche of warrants with two new tranches of warrants (the “Tranche B Warrants” and the “Tranche C Warrants”) as follows: • the Tranche B Warrants are exercisable to acquire 38.5 million common shares at a price of C$ 76.68 per common share; and • the Tranche C Warrants are exercisable to acquire 12.8 million common shares at a price equal to the 5-day volume-weighted average price of the common shares immediately prior to exercise. In connection with the Tranche B Warrants and the Tranche C Warrants, Canopy Growth will provide CBI with a share repurchase credit of up to $ 1.583 billion on the aggregate exercise price of the Tranche B Warrants and Tranche C Warrants in the event that Canopy Growth does not purchase for cancellation the lesser of (i) 27,378,866 common shares; and (ii) common shares with a value of $ 1.583 billion, during the period commencing on April 18, 2019 and ending on the date that is 24 months after the date that CBI exercises all of the Tranche A Warrants. The share repurchase credit feature is accounted for as a derivative liability, with the fair value continuing to be $nil at December 31, 2021. The modifications to the Tranche A Warrants resulted in them meeting the definition of a derivative instrument under ASC 815 - Derivatives and Hedging (“ASC 815”). They continue to be classified in equity as the number of shares and exercise price were both fixed at inception. The Tranche B Warrants are accounted for as derivative instruments measured at fair value in accordance with ASC 815. At December 31, 2021, the fair value of the warrant derivative liability was $ 37,491 (March 31, 2021 – $ 615,575 ), and fair value changes of $ 67,282 and $ 578,084 have been recognized in other income (expense), net in the three and nine months ended December 31, 2021, respectively (three and nine months ended December 31, 2020 – loss of $ 193,998 and $ 93,455 , respectively) (see Note 23). The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 21 for additional details on how the fair value of the warrant derivative liability is calculated on a recurring basis. The Tranche C Warrants are accounted for as derivative instruments, with the fair value continuing to be $nil at December 31, 2021. 28. SEGMENT INFORMATION Reportable segments The Company is reporting its financial results for the following two operating segments, which are also its reportable segments: (i) global cannabis, and (ii) other consumer products. These segments reflect how the Company’s operations are managed, how the Company’s Chief Executive Officer, who is the chief operating decision maker (“CODM”), allocates resources and evaluates performance, and how the Company’s internal management financial reporting is structured. The Company’s global cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Company’s other consumer products segment comprises the production, distribution and sale of consumer products, including (i) Storz & Bickel vaporizers; (ii) This Works beauty, skincare, wellness and sleep products; (iii) BioSteel sports nutrition beverages, mixes, protein, gum and mints; and (iv) other revenue sources. The Company’s CODM evaluates 28 the performance of these two segments focusing on (i) segment net revenue, and (ii) segment gross margin and gross margin percentage as the measure of segment profit or loss. Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Segmented net revenue Global cannabis $ 82,977 $ 103,828 $ 271,241 $ 277,404 Other consumer products 57,995 48,700 137,314 120,806 $ 140,972 $ 152,528 $ 408,555 $ 398,210 Segmented gross margin: Global cannabis $ ( 11,209 ) $ 7,394 $ ( 80,432 ) $ 12,598 Other consumer products 21,299 17,191 46,620 44,562 10,090 24,585 ( 33,812 ) 57,160 Selling, general and administrative expenses 116,835 144,078 355,165 426,723 Share-based compensation 6,777 19,963 35,856 72,632 Expected credit losses on financial assets and relates charges - 13,735 - 108,480 Asset impairment and restructuring costs 36,439 400,422 128,198 459,579 Operating loss ( 149,961 ) ( 553,613 ) ( 553,031 ) ( 1,010,254 ) Loss from equity method investments - ( 671 ) ( 100 ) ( 40,851 ) Other income (expense), net 34,282 ( 290,567 ) 810,769 ( 21,106 ) Net (loss) income before incomes taxes $ ( 115,679 ) $ ( 844,851 ) $ 257,638 $ ( 1,072,211 ) Asset information by segment is not provided to, or reviewed by, the Company’s CODM as it is not used to make strategic decisions, allocate resources, or assess performance. Entity-wide disclosures Disaggregation of net revenue by geographic area: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2021 2020 2021 2020 Canada $ 78,644 $ 91,060 $ 241,440 $ 243,084 Germany 23,143 31,262 71,619 87,649 United States 22,764 18,141 60,856 40,885 Other 16,421 12,065 34,640 26,592 $ 140,972 $ 152,528 $ 408,555 $ 398,210 Disaggregation of property, plant and equipment by geographic area: December 31, March 31, 2021 2021 Canada $ 876,331 $ 847,678 United States 140,299 143,747 Other 63,549 83,112 $ 1,080,179 $ 1,074,537 For the three months ended December 31, 2021, no customer represented more than 10% of the Company’s net revenue (three months ended December 31, 2020 – one ). For the nine months ended December 31, 2021, one customer represented more than 10% of the Company’s net revenue (nine months ended December 31, 2020 – one ). 29. SUBSEQUENT EVENTS Divestiture of C 3 Cannabinoid Compound Company On December 15, 2021, the Company entered into an agreement to divest all of its interest in C 3 Cannabinoid Compound Company GmbH (“C 3 ”) to a European pharmaceutical company headquartered in Germany. C 3 develops and manufactures cannabinoid-based pharmaceutical products for distribution in Germany and certain other European countries. 29 The divestiture was completed on January 31, 2022, pursuant to which the Company received a cash payment of $ 128,316 (€ 88,698 ), inclusive of cash, working capital and debt adjustments . The Company will also be entitled to an earnout payment of up to € 42,600 , subject to the achievement of certain milestones by C 3 . 30